Slide 1: H2 2025 and Full Year 2025 Financial Results
Investor presentation H2 2025 and Full Year 2025 Financial Results Webinar, 26 February 2026
Slide 2: Presenting today
Presenting today Mikko Karvinen Joonas Juokslahti CEO CFO At Nexstim since 2014 At Nexstim since 2014 Previous experience: Previous experience: February 2026 Nexstim Plc – Public presentation 2
Slide 3: The leading nTMS company
The leading nTMS company Technology leader Most advanced technology and product in navigated transcranial magnetic stimulation (“nTMS”) Clinically proven and FDA + CE compliant Strong competitive edge as the only the only diagnostics player holding both FDA and CE approvals in a highly regulated
Slide 4: Nexstim nTMS solutions and business areas
Nexstim nTMS solutions and business areas Business area System Application Business model Customers Revenue from system sales Pre-surgical Diagnostics NBS 5, NBS 6 mapping CE marked FDA approved Recurring revenue from leasing, Depression and maintenance and Therapy NBT®, NBS 6 chronic pain consumabl
Slide 5: Three major use cases for nTMS
Three major use cases for nTMS Therapy Diagnostics Depression Chronic pain Millions of patients do not respond Many chronic pain patients do not Brain surgery risks damaging critical adequately to antidepressant achieve relief with existing speech and motor areas medications medications or therapies
Slide 6: Strategic partnership with leading digital surgery solutions provider
Strategic partnership with leading digital surgery solutions provider Significant milestones in Brainlab partnership Brainlab factsheet ▶ Leading global provider of digital surgery Top management and medical navigation solutions Strategic partnership and First marketing launch live First commercial
Slide 7: Promising Alzheimer's therapy collaboration with leading neurotech company Sinaptica
Promising Alzheimer’s therapy collaboration with leading neurotech company Sinaptica Entering the fast-growing Alzheimer’s therapy market Sinaptica factsheet ▶ Leading neurotechnology company Co-development Exclusivity Agreement developing non-invasive brain stimulation Positive Phase II with Sinapt
Slide 8: 2025 Financial Performance and 2026 Guidance
2025 Financial Performance and 2026 Guidance Key Performance Indicators Key notes 7–12/2025 7–12/2024 1–12/2025 1–12/2024 (EUR thousand) Change, % Change, % ▶ The company accelerated the growth pace from the previous 6 months 6 months 12 months 12 months strategy period to 26% (2020-2024 CAGR: 21%)
Slide 9: Strong momentum fueled by accelerating device sales
Strong momentum fueled by accelerating device sales Therapy Diagnostics Therapeutics KPIs # of devices sold since H1 ’20(1), cumulative Alzheimer study Sales CAGR ’20-’25 – 18% cooperation with Recurring revenue-%’25 – 55% Sinaptica More than 260 diagnostic and Brainlab cooperation 153 more than 135
Slide 10: Financials – Ramping up for profitable growth
Financials – Ramping up for profitable growth Strong growth with scaling fixed cost base Key operational milestones Net sales (EURm) EBITDA (EURm) +431% Gross margin % 1,7 ▶ Strong revenue momentum, with comparable net sales up +21% CAGR 0,3 since 2022 79% 78% 79% 77% (0,5) ▶ Stable and expanding pr
Slide 11: FY2025 update – delivering growth and global impact
FY2025 update – delivering growth and global impact +23% deliveries growth YoY Strengthening market presence Key highlights Diagnostics (#) ▶ Summary of key events attended during ▶ Strong diagnostics momentum: 19 Therapy (#) H2 2025 systems delivered (+46% YoY) Research – Brain Computer Interface (
Slide 12: NBS 6 launch driving accelerating sales momentum
NBS 6 launch driving accelerating sales momentum Launch in 2023 for Therapy Diagnostics launch in October 2025 Key takeaways # of devices sold, cumulative ▶ The NBS 6 is a new combined system The NBS 6 launch for 30 that has been built on Nexstim’s unique, Therapy has been clinically established tec
Slide 13: Strong momentum with several growth catalysts
Strong momentum with several growth catalysts +43% 3,8 2,7 NBS 6 2021 2025 Recurring revenue (EURm) Leveraging FDA and CE Increasing system sales Launching the new NBS 6 Major market opportunity Increasing installed base approvals to grow volume through Brainlab diagnostics system and for treatment
Slide 14: Key investment highlights and strategic objective
Key investment highlights and strategic objective Broad and attractive market with multiple clinical Strategic Objectives 2026 1 use cases Leading proprietary technology with key ▶ Profitable growth: Increase net sales and 2 improve operating result for the financial year, regulatory approvals while
Slide 15: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj obligation to update or revise this document. (“Nexstim” or the “Company”). In connection with any presentation or review of this document, you agree to be bound by the following limitations a
Slide 16: Appendix
Appendix Nexstim Plc – Public presentation
Slide 17: Consolidated Income Statement
Consolidated Income Statement EURk 2022 2023 2024 2025 Net sales 9,526.7 7,246.3 8,735.4 10,968.8 Capitalised fixed assets 1,235.7 1,338.6 1,477.9 1,444.2 Other operating income 34.0 10.8 74.1 6.2 Materials and services Purchases during the period (1,143.9) (1,749.1) (1,584.4) (2,265.0) Change in in
Slide 18: Consolidated Balance Sheet
Consolidated Balance Sheet EURk 2022 2023 2024 FY25 EURk 2022 2023 2024 FY25 ASSETS EQUITY AND LIABILITIES NON-CURRENT ASSETS EQUITY Intangible assets Share capital 80.0 80.0 80.0 80.0 Development expenditure 1,832.3 2,630.2 3,491.5 4,091.7 Reserve for invested unrestricted Intangible rights 280.2 2